TA
FENC icon

Tamarack Advisers’s Fennec Pharmaceuticals FENC Stock Holding History

Tamarack Advisers’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-149,200
Closed -$1.24M – 37
2023
Q1 		$1.24M Sell
149,200
-63,800
-30% -$592K 0.45% 28
2022
Q4 		$2.04M Buy
213,000
+38,000
+22% +$336K 1.05% 28
2022
Q3 		$1.42M Buy
+175,000
New +$1.2M 0.83% 31

Other funds holding FENC

SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SGL
Sonic GP LLC Honolulu, Hawaii $45.4M AUM 5.08% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HFA
Harbert Fund Advisors Birmingham, Alabama $3.03M AUM 40.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return

Tamarack Advisers's FENC Position: Q2 2023 in Review

Tamarack Advisers sold out of Fennec Pharmaceuticals (FENC) in Q2 2023, closing a stake of 149,200 shares — an estimated $1.24M sold.

Tamarack Advisers first reported a position in FENC in Q3 2022 and held it in 3 quarters. The position peaked at $2.04M in Q4 2022. 56 funds tracked by Wall St. Rank hold FENC as of Q2 2023.

  • Tamarack Advisers reported no remaining Fennec Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Tamarack Advisers sold 149,200 Fennec Pharmaceuticals shares in Q2 2023, an estimated $1.24M.
  • Tamarack Advisers first reported a position in Fennec Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Tamarack Advisers's Fennec Pharmaceuticals position peaked at $2.04M in Q4 2022.
  • 56 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2023.

Based on Tamarack Advisers's 13F filing for Q2 2023, filed 10 Aug 2023.